All In Biotech

Drug Trial Radar · NCT03982368

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

261

Actual

Start

Jun 10, 2019

Primary completion

Jul 15, 2020

Study completion Jul 15, 2020

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Jun 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.

Conditions

  • Dry Eye Syndrome

Interventions

  • rhNGF 20 μg/mlDrug

    one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)

  • rhNGF 20 μg/ml + vehicleDrug

    one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours). rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.

  • VehicleOther

    one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Schirmer I Test (Without Anesthesia) vs Week 4 - Full Analysis SetTime frame: Baseline, week 4
  2. Change From Baseline in Schirmer I Test (Without Anesthesia) vs Week 4 - Per Protocol SetTime frame: Baseline, week 4

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Global Research Management

    Glendale, California

  • Eye Research Foundation

    Newport Beach, California

  • Martel Eye Medical Group

    Rancho Cordova, California

  • Sierra Clinical Trials & Research Organization

    Santa Ana, California

  • Clayton Eye Clinical Research, LLC

    Morrow, Georgia

  • Kentucky Eye Institute

    Lexington, Kentucky

  • Tauber Eye Center

    Kansas City, Missouri

  • Moyes Eye Center

    Kansas City, Missouri

  • SightMD

    Babylon, New York

  • Toyos Clinic

    Nashville, Tennessee

  • Houston Eye Associates HEA - Gramercy Location

    Houston, Texas

  • Advanced Laser Vision Surgical Institute (Study Site) Intouch Clinical Research Center (SMO)

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.